Drug intelligence / Profile preview

diosmin + hesperidin

Development stage
Phase 4
Lead developer
Hasan-Dermapharm
Modality
Small Molecules
Administration
Oral
01

Overview

Hasanflon is a generic phlebotonic and vascular-protecting medication developed and marketed by Hasan-Dermapharm. It consists of a micronized purified flavonoid fraction (MPFF), typically containing 90% diosmin and 10% hesperidin. Hasanflon is indicated for the treatment of symptoms related to chronic venous insufficiency (CVI), such as heavy legs, pain, and nocturnal cramps, as well as for the management of acute hemorrhoidal attacks. The drug's mechanism of action involves increasing venous tone by prolonging the vasoconstrictor effect of noradrenaline on the venous wall, improving lymphatic drainage, and protecting the microcirculation by reducing capillary permeability and inhibiting inflammatory mediators.

Brand names
HasanflonHasanflon 500Hasanflon500Hasanflon-500
Other names
Micronized purified flavonoid fractionMPFF
02

Targets

AcetylcholinesteraseAHR (Aryl hydrocarbon receptor)COMT (Catechol-O-methyltransferase)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PDE (Phosphodiesterase family)AR (Adrenergic receptors)

Beyond the preview

Go deeper on diosmin + hesperidin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diosmin + hesperidin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call